Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Mark

"The implications of the Quanta decision will extend across many industries. Patentees and licensees will want to reexamine their licensing arrangements and practices to determine whether the relevant patents are exhausted by the form of a sale. Even if patent rights are exhausted, a patentee may still be able to enforce restrictions through contractual terms, although the Court did not address the permitted scope of such terms. The permissible scope of such terms will need to await later decisions."

I believe that TPL has different types of Licenses and they are very clear in their contracts.

I also believe that the J3 case went the way it did because our patents were still tied up in the USPTO and NOT because were were concerned that a WIN over the J3 would be overturned on the basis of the Quanta case.

Corrections welcome.



Share
New Message
Please login to post a reply